Similar articles

• Protein tyrosine kinase inhibitors: new treatment modalities?

  Fabbro D, Parkinson D, Matter A. Fabbro D, et al. Curr Opin Pharmacol. 2002 Aug;2(4):374-81. doi: 10.1016/s1471-4892(02)00179-0. Curr Opin Pharmacol. 2002. PMID: 12127869 Review.
• New drug targets genetic malfunction in chronic myeloid leukemia.

  [No authors listed] [No authors listed] Am J Health Syst Pharm. 2001 Jul 15;58(14):1282. doi: 10.1093/ajhp/58.14.1282. Am J Health Syst Pharm. 2001. PMID: 11471471 No abstract available.
• Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).

  Chrobák L, Voglová J. Chrobák L, et al. Acta Medica (Hradec Kralove). 2003;46(3):85-9. Acta Medica (Hradec Kralove). 2003. PMID: 14677715 Review.
• [Molecular targeting therapy of hematopoietic tumors].

  Matsumura I, Kanakura Y. Matsumura I, et al. Nihon Naika Gakkai Zasshi. 2006 Jul 10;95(7):1375-81. doi: 10.2169/naika.95.1375. Nihon Naika Gakkai Zasshi. 2006. PMID: 16893036 Review. Japanese. No abstract available.
• Targeted cancer therapies in the twenty-first century: lessons from imatinib.

  Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Stegmeier F, et al. Clin Pharmacol Ther. 2010 May;87(5):543-52. doi: 10.1038/clpt.2009.297. Epub 2010 Mar 17. Clin Pharmacol Ther. 2010. PMID: 20237469 Review.